Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2024.02.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcatheter Edge-to-Edge Repair of Common Atrioventricular Valve Regurgitation in the Setting of a Lateral Tunnel Fontan Circulation.
Struct Heart
November 2024
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
•Percutaneous repair of severely regurgitant atrioventricular valves in the setting of a Fontan circulation utilizing Tri-Clip, even in the setting of an atrioventricular septal defect, is feasible.•Percutaneous options hold promise as a low-risk repair strategy in this highly complex population, which generally has a high surgical risk.
View Article and Find Full Text PDFTranscatheter Repair of Tricuspid Valve Regurgitation: A Systematic Review.
J Clin Med
October 2024
Structural Heart & Valve Center, Houston Heart, HCA Houston Healthcare Medical Center, Tilman J. Fertitta Family College of Medicine, The University of Houston, Houston, TX 77004, USA.
Clinically significant severe tricuspid regurgitation (TR) is a common untreated pathology associated with increased mortality. Even though surgical valve replacement has been the mainstay option, transcatheter intervention is a novel and potentially effective tool. To the best of our knowledge, this is the first systematic review that assessed and compared clinical and echocardiographic outcomes of coaptation and annuloplasty devices in patients with clinically significant TR.
View Article and Find Full Text PDFReal-World Patient Eligibility and Feasibility of Transcatheter Edge-to-Edge Repair or Replacement Interventions for Tricuspid Regurgitation.
J Card Fail
October 2024
Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address:
Article Synopsis
- Novel transcatheter therapies for tricuspid regurgitation (TR) show promise, but their suitability for the general TR patient population is still uncertain.
- In a study involving 178 patients with moderate symptomatic TR, only 10.7% qualified for investigative therapies, while many received off-label clipping, surgery, or medical treatment due to factors like unsuitable anatomy or existing health issues.
- Although the investigative group experienced significant improvement in TR severity after one year compared to the medical treatment group, their outcomes were similar to off-label clipping but not as favorable as surgery, highlighting the need for broader access to effective therapies for TR patients.
Case report: Transcatheter edge-to-edge repair after prior surgical tricuspid annuloplasty.
Front Cardiovasc Med
October 2022
Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, University Düsseldorf, Dūsseldorf, Germany.
Residual and recurrent tricuspid regurgitation may occur frequently after surgical tricuspid valve repair. However, reoperation for tricuspid regurgitation is rare, although many patients are again highly symptomatic. Tricuspid transcatheter edge-to-edge repair (TEER) is a promising therapy for severe tricuspid regurgitation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!